Four-year data from Genentech’s Rhone-X extension study showed 80% of participants with diabetic macular oedema (DMO) treated with Vabysmo (faricimab-svoa) extended their treatment intervals to every three or four months.
Presenting results at the American Society of Retina Specialists 2024 annual meeting in Sweden, the company also reported Vabysmo was well tolerated, continued to preserve vision and dry retinal fluid. These data reinforce Vabysmo’s potential to become the standard of care treatment for DMO, said Dr Levi Garraway, Genentech’s chief medical officer and head of global product development. “We are especially pleased to see that nine out of 10 patients showed no sign of DMO after four years of treatment with Vabysmo, which is an incredible long-term outcome for people living with this condition.”
